Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:

NCT ID: NCT05378737 Recruiting - Clinical trials for Advanced Solid Tumors

Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection

Start date: July 6, 2022
Phase: Phase 1
Study type: Interventional

Objectives: To evaluate the safety and tolerability of BAT8006 for injection in patients with advanced solid tumors, explore the maximum tolerated dose (MTD), and provide the recommended dose for subsequent clinical trials.

NCT ID: NCT05367635 Recruiting - Clinical trials for Advanced Solid Tumors

A Study of SKB315 in Patients With Advanced Solid Tumors

Start date: March 16, 2022
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, multiple-dose dose finding and expansion study to evaluate the safety, tolerability, pharmacokinetic(PK) profile, and anti-tumor efficacy of SKB315 for injection in patients with advanced solid tumors.

NCT ID: NCT05338346 Recruiting - Clinical trials for Advanced Solid Tumors

A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies

ATRIUM
Start date: July 8, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase I, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR inhibitor) Treatment in Patients with Advanced Solid Tumors and Hematological Malignancies .

NCT ID: NCT05320640 Recruiting - Clinical trials for Advanced Solid Tumors

Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors

Start date: March 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial aims to evaluate safety and efficacy of Chidamide, Decitabine and Immune checkpoint inhibitors in relapsed/refractory Non-Hodgkin Lymphoma and advanced solid tumors.

NCT ID: NCT05287399 Recruiting - Clinical trials for Advanced Solid Tumors

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors

Start date: August 2, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, multicenter, single-arm, dose escalation study, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of single-agent ASC61(an orally bioavailable small-molecule inhibitor of PD-L1) in subjects with advanced solid tumors for whom no standard therapy is available.

NCT ID: NCT05287165 Recruiting - Clinical trials for Advanced Solid Tumors

Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms

Start date: March 10, 2022
Phase: Early Phase 1
Study type: Interventional

This is a open-label, single center to determine the efficacy and safety of IM96 CAR-T cells in Patients With Advanced Digestive System Neoplasms

NCT ID: NCT05278832 Recruiting - Clinical trials for Advanced Solid Tumors

A Study of QLS31905 in Patients With Advanced Solid Tumors

Start date: October 25, 2021
Phase: Phase 1
Study type: Interventional

This is a multi-center, open-label design to evaluate the safety and tolerance of QLS31905 in patients with advanced solid tumors, together with an assessment of pharmacokinetic characteristics and efficacy.

NCT ID: NCT05277168 Recruiting - Clinical trials for Advanced Solid Tumors

A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS

Start date: May 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The study (dose escalation/expansion) is being conducted to assess the safety and tolerability of SHR-A1904 in subjects with advanced solid tumors, and to determine maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D), to assess preliminary efficacy of SHR-A1904, pharmacokinetic (PK) profile and immunogenicity of SHR-A1904 in subjects with advanced solid tumors.

NCT ID: NCT05275062 Recruiting - Pancreatic Cancer Clinical Trials

Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma

Start date: February 15, 2022
Phase: Early Phase 1
Study type: Interventional

This is a open-label, single center to determine the efficacy and safety of IM92 CAR-T cells in Patients With advanced gastric/esophagogastric combination adenocarcinoma that has failed at least second-line therapy and advanced pancreatic cancer that has failed at least first-line therapy.

NCT ID: NCT05272709 Recruiting - Clinical trials for Advanced Solid Tumors

TT-702 in Patients With Advanced Solid Tumours.

CURATE
Start date: January 19, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical trial is evaluating the drug candidate TT-702 in patients with advanced solid tumours. The main aims of the trial are to determine the maximum dose of TT-702 that can be given safely to patients alone and in combination with other anti-cancer agents.